The US IPO market produced seven IPOs in January 2013—the busiest start to the year since 2006. Buoyed by the $2.2 billion IPO of Pfizer’s animal health unit Zoetis, gross proceeds in January were $3.3 billion—the highest January figure since 2000. The month included IPOs by well-established companies with proven revenue and profitability as well as a trio of biotech offerings.
The average first-day gain for January’s IPOs was 18% compared to 16% for all IPOs in 2012. Norwegian Cruise Line, Bright Horizons and Zoetis enjoyed first-day gains of 30%, 29% and 19%, respectively—these gains were all the more striking because each offering was priced above the range. There were no “broken” IPOs (IPOs whose stock closes below the offering price on their opening day) in the month.
With offerings by KaloBios Pharmaceuticals, LipoScience and Stemline Therapeutics during the last week of January, the biotech IPO market began the year with a solid start. LipoScience and Stemline rose 16% and 18%, respectively, in first-day trading while KaloBios was flat. Each of these IPOs priced at the bottom of the range.
The remaining January IPO was by Starwood-backed homebuilder TRI Pointe Homes, which saw a 12% first-day gain after pricing above the range.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
FinCEN notified U.S. financial institutions that the Financial Action Task Force updated the list of jurisdictions with strategic anti-money laundering ("AML")/countering the financing of terrorism deficiencies.
The last thirty years have witnessed a dramatic rise in bank adoption of the bank holding company ("BHC") structure. Inherent in this trend is an apparent accepted orthodoxy about the need of such structures from both a business and regulatory perspective.
Recent years have been marked by low interest rates and a highly liquid loan market, creating a very favorable environment for leveraged loans used to fund mergers and acquisitions, sometimes in conjunction with large one-time dividend payouts.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).